State Street Corp Sells 337,262 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

State Street Corp reduced its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 12.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,371,271 shares of the company’s stock after selling 337,262 shares during the quarter. State Street Corp owned 3.35% of Nurix Therapeutics worth $53,282,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 31.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares in the last quarter. Quarry LP boosted its position in Nurix Therapeutics by 3,746.2% during the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after acquiring an additional 2,435 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Nurix Therapeutics by 1,098.4% during the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after acquiring an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC raised its holdings in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the last quarter.

Analyst Ratings Changes

NRIX has been the subject of several recent research reports. HC Wainwright increased their target price on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Oppenheimer raised their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. BTIG Research initiated coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. BMO Capital Markets initiated coverage on Nurix Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $35.00 price target for the company. Finally, Stephens reiterated an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.35.

Nurix Therapeutics Trading Down 4.4 %

Nurix Therapeutics stock opened at $20.24 on Thursday. The company has a market capitalization of $1.43 billion, a price-to-earnings ratio of -6.96 and a beta of 2.11. The stock’s 50 day moving average is $23.58 and its 200-day moving average is $22.28. Nurix Therapeutics, Inc. has a 12 month low of $7.65 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of Nurix Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $614,800. The trade was a 11.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Houte Hans Van sold 2,368 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the sale, the chief financial officer now directly owns 37,270 shares in the company, valued at approximately $905,661. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,401 shares of company stock worth $437,453 in the last quarter. 7.20% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.